Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Nina Shah(The University of Texas MD Anderson Cancer Center), Krina K. Patel(University of Vermont), Wildaliz Nieves(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Craig C. Hofmeister(The Ohio State University), Gregory Orloff(Virginia Cancer Specialists), Taewoong Choi(Duke University), Hayder Saeed(University of Kentucky), Qiang Zhao(First Affiliated Hospital of Zhengzhou University), Mario Q. Marcondes(Nektar Therapeutics (United States)), Jing C. Ye(University of Michigan), David A. Rizzieri(Duke University), Mary Tagliaferri(Nektar Therapeutics (United States)), Kazuharu Kai(Nektar Therapeutics (United States)), Alan Tan(Unknown), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Julio C. Chávez(Moffitt Cancer Center), Xiaoli Wang(First Affiliated Hospital of Jiangxi Medical College), Andrew J. Cowan(University of Washington), Zachary Lee(Nektar Therapeutics (United States)), Elizabeth Budde(City of Hope), Neha Dixit(Nektar Therapeutics (United States)), Mitchell S. Cairo(New York Medical College)
Cited by 4
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k